Section 6 of 6
References
206 sources
- Alban et al. (2025) (opens in a new tab)
- Alfaar et al. (2025) (opens in a new tab)
- Algazi et al. (2016) (opens in a new tab)
- American Cancer Society eye cancer survival rates (2025) (opens in a new tab)
- American Cancer Society key statistics for eye cancer (2026) (opens in a new tab)
- Atkinson et al. (2017) (opens in a new tab)
- Bakalian et al. (2008) (opens in a new tab)
- Barbor (2026) (opens in a new tab)
- Bauer et al. (2022) (opens in a new tab)
- Bedikian et al. (2003) (opens in a new tab)
- BioSpace (2026) (opens in a new tab)
- Bristol-Myers Squibb OPDIVO prescribing information (2026) (opens in a new tab)
- Bristol-Myers Squibb OPDUALAG prescribing information (2026) (opens in a new tab)
- Bristol-Myers Squibb YERVOY prescribing information (2026) (opens in a new tab)
- Brown et al. (2022) (opens in a new tab)
- Brown et al. (2023) (opens in a new tab)
- Buder et al. (2013) (opens in a new tab)
- CADTH pharmacoeconomic review, tebentafusp (2023) (opens in a new tab)
- CADTH rapid response report, radioembolization for uveal melanoma liver metastases (2018) (opens in a new tab)
- CADTH reimbursement recommendation, tebentafusp (2023) (opens in a new tab)
- Campbell et al. (2026) (opens in a new tab)
- Carvajal et al. (2014) (opens in a new tab)
- Carvajal et al. (2018) (opens in a new tab)
- Carvajal et al. (2022) (opens in a new tab)
- Carvajal et al. (2023) (opens in a new tab)
- Castle Biosciences Form 10-K (2026) (opens in a new tab)
- Chen et al. (2014) (opens in a new tab)
- Cheng et al. (2017) (opens in a new tab)
- ClinicalTrials.gov NCT02601378 (opens in a new tab)
- ClinicalTrials.gov NCT03070392 API record (opens in a new tab)
- ClinicalTrials.gov NCT03947385 (opens in a new tab)
- ClinicalTrials.gov NCT05987332 (opens in a new tab)
- ClinicalTrials.gov NCT05987332 version 1 (opens in a new tab)
- ClinicalTrials.gov NCT05987332 version 39 (opens in a new tab)
- ClinicalTrials.gov NCT06581406 (opens in a new tab)
- CMS Local Coverage Determination L37130, MolDX: DecisionDx-UM (2025) (opens in a new tab)
- CMS Quality ID 509 measure specification (2025) (opens in a new tab)
- Collaborative Ocular Melanoma Study Group (2001) (opens in a new tab)
- Damato et al. (2012) (opens in a new tab)
- de Melo et al. (2024) (opens in a new tab)
- Delcath HEPZATO KIT prescribing information (2023) (opens in a new tab)
- Delcath Systems Form 10-K (2026) (opens in a new tab)
- Diener-West et al. (2004) (opens in a new tab)
- Diener-West et al. (2005) (opens in a new tab)
- Dimitriou et al. (2025) (opens in a new tab)
- Eleuteri et al. (2021) (opens in a new tab)
- Ellis et al. (2000) (opens in a new tab)
- EMA orphan designation EU/3/25/3122 (2025) (opens in a new tab)
- Eskelin et al. (1999) (opens in a new tab)
- Eskelin et al. (2002) (opens in a new tab)
- EU CTIS 2023-506686-66-01 (opens in a new tab)
- European Medicines Agency KIMMTRAK orphan maintenance assessment report (2022) (opens in a new tab)
- FDA draft guidance on accelerated approval of oncology therapeutics (2023) (opens in a new tab)
- FDA guidance page, accelerated approval of oncology therapeutics (2023) (opens in a new tab)
- FDA guidance, Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics (2018) (opens in a new tab)
- FDA Orphan Drug Designations and Approvals (2022) (opens in a new tab)
- FDA SeCore CDx HLA Sequencing System De Novo decision summary (2022) (opens in a new tab)
- FDA UNII record E0YF0M8O09 (opens in a new tab)
- G-BA resolution, tebentafusp reassessment D-995 (2024) (opens in a new tab)
- García-Mulero et al. (2023) (opens in a new tab)
- Gardner et al. (2014) (opens in a new tab)
- Garg et al. (2022) (opens in a new tab)
- Gonsalves et al. (2019) (opens in a new tab)
- Harbour et al. (2010) (opens in a new tab)
- HAS Transparency Committee opinion, KIMMTRAK (2023) (opens in a new tab)
- Hassel et al. (2023a) (opens in a new tab)
- Hassel et al. (2023b) (opens in a new tab)
- Haystack Project press release, uveal melanoma Patient Oriented Value report (2022) (opens in a new tab)
- Heppt et al. (2017) (opens in a new tab)
- Heppt et al. (2019) (opens in a new tab)
- Hikma Dacarbazine for Injection prescribing information (2020) (opens in a new tab)
- Honoré et al. (2026) (opens in a new tab)
- Hu et al. (2005) (opens in a new tab)
- Hughes et al. (2016) (opens in a new tab)
- IDEAYA Biosciences clinical trials and expanded access policy (opens in a new tab)
- IDEAYA Biosciences corporate presentation, November 2026 (2026) (opens in a new tab)
- IDEAYA Biosciences Form 10-K (2025) (opens in a new tab)
- IDEAYA Biosciences Form 10-K (2026) (opens in a new tab)
- IDEAYA Biosciences Form 10-Q, first quarter 2026 (2026) (opens in a new tab)
- IDEAYA Biosciences Form 10-Q, third quarter 2026 (2026) (opens in a new tab)
- IDEAYA Biosciences Form 8-K, Servier license agreement (2025) (opens in a new tab)
- IDEAYA Biosciences press release, 2026 corporate objectives (2026) (opens in a new tab)
- IDEAYA Biosciences press release, End-of-Phase 1 meeting with FDA (2019) (opens in a new tab)
- IDEAYA Biosciences press release, ESMO 2023 phase 2 results (2023) (opens in a new tab)
- IDEAYA Biosciences press release, ESMO 2026 data (2026) (opens in a new tab)
- IDEAYA Biosciences press release, Fast Track designation (2022) (opens in a new tab)
- IDEAYA Biosciences press release, FDA Type C meeting and interim phase 2 data (2023) (opens in a new tab)
- IDEAYA Biosciences press release, first quarter 2026 results (2026) (opens in a new tab)
- IDEAYA Biosciences press release, first-line OptimUM-01 overall survival at SMR 2025 (2025) (opens in a new tab)
- IDEAYA Biosciences press release, fourth quarter and full year 2025 results (2026) (opens in a new tab)
- IDEAYA Biosciences press release, IDMC move-forward dose recommendation (2024) (opens in a new tab)
- IDEAYA Biosciences press release, OptimUM-02 ASCO 2026 data (2026) (opens in a new tab)
- IDEAYA Biosciences press release, OptimUM-02 full enrollment (2025) (opens in a new tab)
- IDEAYA Biosciences press release, OptimUM-02 topline results (2026) (opens in a new tab)
- IDEAYA Biosciences press release, OptimUM-11 first patient dosed (2026) (opens in a new tab)
- IDEAYA Biosciences press release, phase 2 expansion dose data in pretreated metastatic uveal melanoma (2021) (opens in a new tab)
- IDEAYA Biosciences press release, Real-Time Oncology Review (2026) (opens in a new tab)
- IDEAYA Biosciences press release, second quarter 2026 results (2026) (opens in a new tab)
- IDEAYA Biosciences press release, third quarter 2026 results (2026) (opens in a new tab)
- IDEAYA Biosciences press release, updated OptimUM-02 topline guidance (2026) (opens in a new tab)
- Immunocore Form 10-K (2026) (opens in a new tab)
- Immunocore KIMMTRAK prescribing information (2024) (opens in a new tab)
- Immunocore KIMMTRAK price change notice (2026) (opens in a new tab)
- Jager et al. (2020) (opens in a new tab)
- Jochems et al. (2019) (opens in a new tab)
- Johansson et al. (2016) (opens in a new tab)
- Johnson et al. (2019) (opens in a new tab)
- Joseph et al. (2026) (opens in a new tab)
- Kentucky Department for Medicaid Services clinical diagnostic laboratory fee schedule (2026) (opens in a new tab)
- Khoja et al. (2019) (opens in a new tab)
- Kim et al. (2010) (opens in a new tab)
- Koumprentziotis et al. (2026) (opens in a new tab)
- Kujala et al. (2003) (opens in a new tab)
- Labcorp test 167107, HLA A A*02:01-Specific (opens in a new tab)
- Lane et al. (2018) (opens in a new tab)
- Lanzafame et al. (2026) (opens in a new tab)
- Leyvraz et al. (2014) (opens in a new tab)
- Liu et al. (2026) (opens in a new tab)
- Luckett et al. (2025) (opens in a new tab)
- Luke et al. (2020) (opens in a new tab)
- Luo et al. (2023) (opens in a new tab)
- Mahendraraj et al. (2017) (opens in a new tab)
- Maio et al. (2013) (opens in a new tab)
- Mariani et al. (2009) (opens in a new tab)
- McKean et al. (2023) (opens in a new tab)
- McKean et al. (2025) (opens in a new tab)
- McKean et al. (2026a) (opens in a new tab)
- McKean et al. (2026b) (opens in a new tab)
- MedlinePlus crizotinib drug information (2022) (opens in a new tab)
- Melia et al. (2001) (opens in a new tab)
- Merck KEYTRUDA cost information (2026) (opens in a new tab)
- Merck KEYTRUDA prescribing information (2026) (opens in a new tab)
- Moore et al. (2016) (opens in a new tab)
- Najjar et al. (2020) (opens in a new tab)
- Nathan et al. (2021) (opens in a new tab)
- National Cancer Institute intraocular melanoma treatment PDQ (2025) (opens in a new tab)
- National Comprehensive Cancer Network Uveal Melanoma guideline (opens in a new tab)
- NCI Drug Dictionary (opens in a new tab)
- Ng et al. (2024) (opens in a new tab)
- NHS England evidence summary, chemosaturation for liver metastases from ocular melanoma (2015) (opens in a new tab)
- NICE resource impact summary report, tebentafusp (2025) (opens in a new tab)
- NICE technology appraisal guidance TA1027, committee discussion (2025) (opens in a new tab)
- NICE technology appraisal guidance TA1027, information about tebentafusp (2025) (opens in a new tab)
- NICE technology appraisal guidance TA1027, recommendations (2025) (opens in a new tab)
- Ocumel Canada survey report, the ocular melanoma landscape in Canada (2021) (opens in a new tab)
- Olofsson Bagge et al. (2023) (opens in a new tab)
- Olofsson Bagge et al. (2025) (opens in a new tab)
- OncLive (2026) (opens in a new tab)
- Onken et al. (2012) (opens in a new tab)
- Orloff et al. (2026a) (opens in a new tab)
- Orloff et al. (2026b) (opens in a new tab)
- Ott et al. (2026a) (opens in a new tab)
- Ott et al. (2026b) (opens in a new tab)
- Pelster et al. (2021) (opens in a new tab)
- Pfizer XALKORI Connecticut price disclosure (2026) (opens in a new tab)
- Pfizer XALKORI prescribing information (2023) (opens in a new tab)
- Pham et al. (2023) (opens in a new tab)
- Piperno-Neumann et al. (2016) (opens in a new tab)
- Piperno-Neumann et al. (2020) (opens in a new tab)
- Piperno-Neumann et al. (2023) (opens in a new tab)
- Piperno-Neumann et al. (2025) (opens in a new tab)
- Piperno-Neumann et al. (2026a) (opens in a new tab)
- Piperno-Neumann et al. (2026b) (opens in a new tab)
- Piperno-Neumann et al. (2026c) (opens in a new tab)
- Piulats et al. (2021) (opens in a new tab)
- Piulats et al. (2024) (opens in a new tab)
- Radivoyevitch et al. (2021) (opens in a new tab)
- Rantala et al. (2019) (opens in a new tab)
- Rantala et al. (2021) (opens in a new tab)
- Rantala et al. (2022) (opens in a new tab)
- Resnick (2026) (opens in a new tab)
- Ribeiro et al. (2023) (opens in a new tab)
- Robertson et al. (2017) (opens in a new tab)
- Rodrigues et al. (2018) (opens in a new tab)
- Rodrigues et al. (2025) (opens in a new tab)
- Rola et al. (2022) (opens in a new tab)
- Rossi et al. (2019) (opens in a new tab)
- Roth et al. (2024) (opens in a new tab)
- Rowcroft et al. (2020) (opens in a new tab)
- Sacco et al. (2024a) (opens in a new tab)
- Sacco et al. (2024b) (opens in a new tab)
- Salama et al. (2026) (opens in a new tab)
- Sato et al. (2025) (opens in a new tab)
- Schinzari et al. (2017) (opens in a new tab)
- Schuermeyer et al. (2016) (opens in a new tab)
- Scottish Medicines Consortium advice SMC2910, tebentafusp (2026) (opens in a new tab)
- Shoushtari et al. (2021) (opens in a new tab)
- Siegel et al. (2026) (opens in a new tab)
- Steckler et al. (2022) (opens in a new tab)
- Steeb et al. (2018) (opens in a new tab)
- Tong et al. (2024) (opens in a new tab)
- Valsecchi et al. (2015) (opens in a new tab)
- van den Hoek et al. (2026) (opens in a new tab)
- van der Kooij et al. (2025) (opens in a new tab)
- Van Raamsdonk et al. (2010) (opens in a new tab)
- Vigneswaran et al. (2024) (opens in a new tab)
- Visser et al. (2024) (opens in a new tab)
- Wagle et al. (2021) (opens in a new tab)
- Wei et al. (2022) (opens in a new tab)
- Weinberger et al. (2025) (opens in a new tab)
- WHO Collaborating Centre ATC/DDD Index (2026) (opens in a new tab)
- Xu et al. (2019) (opens in a new tab)
- Yamada et al. (2024) (opens in a new tab)
- Zager et al. (2024) (opens in a new tab)
- Zager et al. (2025) (opens in a new tab)
- Zimmer et al. (2015) (opens in a new tab)